Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus: Closer to a Cause?

Samantha C. Shapiro, MD  |  September 20, 2024

Dr. Choi: We are actively working on trying to utilize these technologies to develop novel drugs. It is a key priority for our labs.

TR: Might drugs that stimulate AHR have implications for other autoimmune diseases besides lupus?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Rao: Expansion of TPH cells and activated B cells occurs in many autoantibody-associated autoimmune diseases, including rheumatoid arthritis, Sjögren’s disease and others. It seems likely that strategies that inhibit the T cell-B cell response, including through the activation of AHR, could be beneficial across several of these diseases. 

Conclusion

SLE is complicated for patients and providers alike. Studies like these pave the way for a better understanding, and a better understanding paves the way for better treatment. It’s an exciting time to be a rheumatologist.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Samantha C. Shapiro, MD, is a clinician educator who is passionate about the care and education of rheumatology patients. She writes for both medical and lay audiences and practices telerheumatology.

References

  1. Gulati G, Brunner HI. Environmental triggers in systemic lupus erythematosus. Semin Arthritis Rheum. 2018 Apr;47(5):710–717.
  2. Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci. 2023 Mar 31;24(7):6578.
  3. Xing M, Ma Y, Cui F, et al. Air pollution, genetic susceptibility, and risk of incident systemic lupus erythematosus: A prospective cohort study. Arthritis Rheumatol. 2024 Jul 10. Online ahead of print.
  4. Glencross DA, Ho TR, Camiña N, et al. Air pollution and its effects on the immune system. Free Radic Biol Med. 2020 May 1;151:56–68.
  5. Rezayat AA, Niloufar jafari, Mir Nourbakhsh SH, et al. The effect of air pollution on systemic lupus erythematosus: A systematic review and meta-analysis. Lupus. 2022 Nov;31(13):1606–1618.
  6. Mai CH, Shih YJ, Lin CL, et al. Associations between fine particulate matter (PM2.5) and childhood-onset systemic lupus erythematosus. Indian J Pediatr. 2022 Feb;89(2):200.
  7. Jung CR, Chung WT, Chen WT, et al. Long-term exposure to traffic-related air pollution and systemic lupus erythematosus in Taiwan: A cohort study. Science of the Total Environment. 2019 Jun 10;668:342–349.
  8. Alarcón-Segovia D, Alarcón-Riquelme ME, Cardiel MH, et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005 Apr;52(4):1138–1147.
  9. Jeong DY, Lee SW, Park YH, et al. Genetic variation and systemic lupus erythematosus: A field synopsis and systematic meta-analysis. Autoimmun Rev. 2018 Jun;17(6):553–566.
  10. Law C, Wacleche VS, Cao Y, et al. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. Nature. 2024 Jul;631(8022):857–866.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:air pollutionenvironmentEULAREULAR 2024Lupussystemic lupus erythematosus (SLE)T cell

Related Articles

    Air Pollution: Is There an Association with Rheumatic Disease?

    December 17, 2015

    Interactions between an individual’s genetic background and their exposure to environmental factors are thought to result in a cascade of immune reactions, ultimately leading to the development of autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and juvenile dermatomyositis.1,2 For example, an environmental factor that conclusively affects susceptibility…

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences